IJBM eISSN 1724-6008
Int J Biol Markers 2015; 30(4): e369-e373 DOI: 10.5301/jbm.5000155
ORIGINAL ARTICLE
Serum cripto-1 as a clinical marker for lung cancer Chun-Hua Xu1,2, Lan Cao2, Ying Wei2, Li-Ke Yu1,2 1 2
Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu - PR China Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu - PR China
Abstract Background: Cripto-1 (CR-1) plays an important role in angiogenesis related to tumor growth, in concert with vascular endothelial growth factor (VEGF), and enhanced expression of CR-1 has been reported in lung cancer tissue. Methods: Patients with lung cancer (n = 156) and healthy volunteers (n = 60) were enrolled in the study. Serum CR-1 and VEGF concentrations were measured using enzyme-linked immunosorbent assay. Results: Patients with lung cancer had higher serum CR-1 (4.03 ± 1.49 ng/mL vs. 1.13 ± 0.43 ng/mL, p
Int J Biol Markers 2015; 30(4): e369-e373 DOI: 10.5301/jbm.5000155
ORIGINAL ARTICLE
Serum cripto-1 as a clinical marker for lung cancer Chun-Hua Xu1,2, Lan Cao2, Ying Wei2, Li-Ke Yu1,2 1 2
Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu - PR China Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu - PR China
Abstract Background: Cripto-1 (CR-1) plays an important role in angiogenesis related to tumor growth, in concert with vascular endothelial growth factor (VEGF), and enhanced expression of CR-1 has been reported in lung cancer tissue. Methods: Patients with lung cancer (n = 156) and healthy volunteers (n = 60) were enrolled in the study. Serum CR-1 and VEGF concentrations were measured using enzyme-linked immunosorbent assay. Results: Patients with lung cancer had higher serum CR-1 (4.03 ± 1.49 ng/mL vs. 1.13 ± 0.43 ng/mL, p
